These include LIBRETTO-432 (NCT04819100), which studies the efficacy of selpercatinib in patients with RET fusion early-stage NSCLC post-surgery or radiation, NAUTIKA1 (NCT04302025), a multicenter, phase II study examining neoadjuvant and adjuvant therapies for biomarker-selected patients with ALK, ROS1, NTRK1/2/3 fusions, BRAF V600E mutation, RET fusions, and KRAS G12C expression and GEOMETRY-N (NCT04926831) trial investigating the use of capmatinib pre- and post-surgery in the patients with MET exon 14 skipping mutation or high MET amplification.8, –10. The gene discussed is ALK; the disease is non-small cell lung carcinoma.